Centessa Pharmaceuticals (CNTA) Retained Earnings (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Retained Earnings data on file, last reported at $1.4 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at $1.4 million, down 32.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 32.14% YoY), and the FY2025 annual result was $2.7 million, up 100.27% from the prior year.
• Retained Earnings slipped to $1.4 million in Q1 2026 per CNTA's latest filing, from $2.7 million in the prior quarter.
• Over five years, Retained Earnings peaked at $2.7 million in Q4 2025 and troughed at -$1.1 billion in Q3 2025.
• A 5-year average of -$470.2 million and a median of -$558.7 million in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 87579.65% in 2022, then soared 100.27% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$601.9 million in 2022, then retreated by 25.1% to -$752.9 million in 2023, then tumbled by 31.31% to -$988.7 million in 2024, then soared by 100.27% to $2.7 million in 2025, then sank by 48.12% to $1.4 million in 2026.
• Business Quant data shows CNTA's Retained Earnings at $1.4 million in Q1 2026, $2.7 million in Q4 2025, and -$1.1 billion in Q3 2025.